FATIMA CARDOSO (Chair)
Champalimaud Clinical Center, Lisbon, PT
Dr. Fatima Cardoso is Chair of ABC Global Alliance, ESO Breast Cancer Programme Coordinator, Coordinating Chair of the ABC ESO-ESMO International Consensus Conference and Director of the Breast Unit of the Champalimaud Clinical Centre in Lisbon, Portugal. Dr. Cardoso is a member of ESMO Board of Directors, Chair of the ESMO National Representatives Committee and Past-Chair of the EORTC-Breast Cancer Group. She is actively involved in further committees from numerous professional organizations and is member of the ESMO Guidelines Steering Committee and of the ESMO Public Policy Steering Committee. She is the Editor-in-Chief of The Breast Journal, Associate Editor of the European Journal of Cancer and an Editorial Board Member of several other journals. She has authored over 280 publications and has presented her work nationally and internationally.
Genolier Cancer Centre, Genolier, CH
Matti Aapro is Executive Board member of the European School of Oncology (ESO) and leads the Sharing Progress in Cancer Care programme and coordinates the activities of ESO in Arab speaking countries and in Latin America.
Dr. Aapro is presently member of the Board of Directors of the Genolier Cancer Center, Genolier, Switzerland.
He is a Board member of ECCO ( European CanCer Organisation ). He serves the International Society for Geriatric Oncology (SIOG) as Executive Board Member. He is past-President
of the Multinational Association for Supportive Care in Cancer (MASCC). He is President of Honour of the French-speaking Society for Supportive Care (AFSOS), as well as Advisor to the Japanese Association for Supportive Care in Cancer (JASCC ). He has been member of the Board of the European Organization for Research and Treatment of Cancer (EORTC) and of the European Society of Medical Oncology (ESMO). He has served UICC ( Union for International Cancer Control ) helping organize the Geneva and Shenzhen congresses.
He is a board member of the Advanced Breast Cancer (ABC) meeting.
BCRF and MBC Alliance, New York, US
Dr. Marc Hurlbert oversees BCRF’s $60-million annual research grants program that supports 275 scientists, from 15 countries and spans all aspects of breast cancer from basic cancer biology and prevention, to developing new treatments and quality of life research. With nearly two decades of nonprofit experience, Marc and his team analyze the research funding landscape, identify gaps and develop strategies to fill gaps and accelerate breast cancer research. Marc also serves as chairman of the Metastatic Breast Cancer Alliance, an (www.mbcalliance.org) an alliance of 30 nonprofit groups, 11 industry partners and individuals living with MBC working together to improve the quality and length of life for patients living with metastatic disease.
Breast Cancer Welfare Association Malaysia (BCWA), Petaling Jaya, MY
Ms Ranjit Kaur, a breast cancer survivor since 1998, and Patient Advocate, is the President of Breast Cancer Welfare Association Malaysia and Chairman of Together Against Cancer Association Malaysia. She is also a Board Member of Reach to Recovery International. Ranjit held the position of President of Reach to Recovery International (2003-2007), and Board Member of the Union for International Cancer Control (UICC) (2006-2010). She regularly gets invited to speak and participate in cancer control conferences locally and internationally.
Breast Cancer Network Australia (ABA patient representative), AU
Breast Cancer Network Australia, Camberwell, AU
Pfizer Inc., New York, US
Maia Thrift-Perry is Chief of Staff for the Strategy & Commercial Operations (StratCO) organization at Pfizer. She provides strategic and operational support for a division responsible for overseeing the shaping of Pfizer’s longer-term strategy, supporting the execution for Pfizer’s commercial objectives, and providing portfolio advisory functions to guide R&D investment decisions.
Maia joined Pfizer in 2011 and most recently was the International Therapeutic Area Lead for the breast and lung cancer portfolios in Global Policy and International Public Affairs. She has more than 10 years of combined international development, policy and public health experience.
Maia holds a Master of Public Health degree from Columbia University, a Master of Arts degree in Women’s Studies from San Diego State University and a Bachelor of Arts degree from Pomona College.
Union for International Cancer Control, Geneva, CH
Dr Torode is Director of Special Projects for the Union for International Cancer Control (UICC). Julie likes to deliver results and work with focus and purpose highlighted by key advocacy wins across the spectrum of care and disciplines in recent years with UICC and NCD Alliance detailed in global commitments in the WHO global action plan on NCDs, the 2017 cancer resolution and the Sustainable Development Goals.
With a PhD in Chemistry from the University of Liverpool and postgraduate work in Education, Julie entered the health arena and field of oncology through leading clinical trials work across phases 1-IV, with a particular focus on breast and gynaecologic cancer while, also nurturing an ongoing interest in cancer prevention. Julie joined UICC in 2008 and has worked in the senior management team to develop the organisation.
European Oncology Nursing Society, London, UK
Professor Theresa Wiseman holds a joint clinical chair of applied health research in cancer care between The Royal Marsden NHS Foundation Trust and the University of Southampton. Nationally she is a member of the UK Department of Health/Macmillan funded Consequence of Cancer and Treatment Collaborative (CCAT). Theresa is an Executive Board Member (secretary) of the European Oncology Nursing Society (EONS) and a member of the EONS Research Advisory Group. She is an international member of Faculty of the Australian and New Zealand Urology Research Group (ANZUP). She is an international invited speaker, has published widely and presented her work nationally and internationally. She is passionate about applied health research but more so that the findings are translated into practice and make a difference to patient care. All her studies to date have been translated to practice.